---
title: "蘇州富士萊醫藥股份有限公司 (301258.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301258.SZ.md"
symbol: "301258.SZ"
name: "蘇州富士萊醫藥股份有限公司"
industry: "制藥"
---

# 蘇州富士萊醫藥股份有限公司 (301258.SZ)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 滬深市場 |
| Website | [www.fuslai.com](https://www.fuslai.com) |

## Company Profile

公司成立于 2000 年，產品以外銷出口為主，已遠銷到歐美、東南亞等國外市場，且國內硫辛酸原料藥市場佔有率名列前茅，已與國內外重要客戶建立長期戰略合作關系。公司主營業務是醫藥中間體、原料藥及保健品原料的研發、生產和銷售。主要產品包括顆粒硫辛酸、R-硫辛酸、R-硫辛酸氨基丁三醇鹽、6,8-二氯辛酸乙酯、甘油磷脂酰膽鹼 (GPC)、L-肌肽、艾瑞昔布原料藥。企業榮譽：安全生產標準化證書、江蘇省科技小巨人企業、食品經營許可證、高新技術企業、中華人民共和國藥品生產許可證、環境管理體系認證證書、高新技術企業、常熟市關心下一代工作優秀集體等。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-15T04:30:09.000Z

**Overall: C (0.43)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 166 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.39% |  |
| Net Profit YoY | 302.42% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.65 |  |
| Dividend Ratio | 0.26% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.16B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 439.12M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.99% | C |
| Profit Margin | 17.28% | A |
| Gross Margin | 13.63% | D |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.39% | C |
| Net Profit YoY | 302.42% | A |
| Total Assets YoY | 3.56% | C |
| Net Assets YoY | 0.98% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 578.69% | C |
| OCF YoY | 6.39% | C |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.21 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 11.27% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 蘇州富士萊醫藥股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.99%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "17.28%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "13.63%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.39%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "302.42%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.56%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.98%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "578.69%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "6.39%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.21",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "11.27%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 興齊眼藥 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恆瑞醫藥 (SH.600276) | A | B | C | A | B | B |
| 04 | 雲南白藥 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 41.64 | 96/222 | 96.99 | 72.10 | 42.09 |
| PB | 1.65 | 42/222 | 1.69 | 1.60 | 1.33 |
| PS (TTM) | 7.19 | 153/222 | 7.34 | 6.93 | 5.79 |
| Dividend Yield | 0.26% | 147/222 | 2.16% | 0.27% | 0.26% |

## References

- [Company Overview](https://longbridge.com/en/quote/301258.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301258.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301258.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.